Recent advances in the cannabinoids

被引：33

作者：

Hertzog, DL ^{[1
]}

机构：

[1] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2004年 / 14卷 / 10期

关键词：

anandamide transporter inhibitor; cannabinoid; CB1; CB2; agonist; antagonist; fatty acid amide hydrolase (FAAH); FAAH inhibitor;

D O I：

10.1517/13543776.14.10.1435

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

This review highlights advances made in cannabinoid chemistry over the time period August 2002 - June 2004. Particular emphasis is placed on new ligands for the CB1 and CB2 receptors. CB1 receptor antagonists have been a prominent area of research for many pharmaceutical companies. Sanofi's CB1 receptor antagonist rimonabant has now generated clinical data demonstrating its efficacy for both obesity and smoking cessation in human subjects. Recent data showing the effects of CB2 agonists for pain in preclinical animal models has been accompanied by the reports from many laboratories disclosing selective CB2 agonists for the treatment of pain and other indications. The further progression of cannabinoid receptor agonists and antagonists into clinical trials will serve to determine the effectiveness of such compounds as therapeutics in the treatment of human diseases and disorders.

引用

页码：1435 / 1452

页数：18

共 110 条

[1] Adam J, 2002, EXPERT OPIN THER PAT, V12, P1475
[2] AKZO NOBEL NV, 2004, Patent No. 2004000832
[3] ALANINE A, 2004, Patent No. 2004013120
[4] *AM COLL CARD, 2004, AM COLL CARD M NEW O
[5] [Anonymous], [No title captured], Patent No. 2004012671
[6] ASTRAZENECA AB, 2002, Patent No. 02085866
[7] ASTRAZENECA AB, 2003, Patent No. 03043619
[8] *AV, 2004, AV 2003 FULL YEAR RE
[9] AVENTIS PHARMA SA, 2002, Patent No. 0223346
[10] AYOUB GS, 2002, Patent No. 0247691

← 1 2 3 4 5 6 7 8 9 10 →